Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
about
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Impact of Socioeconomic Inequality on Access, Adherence, and Outcomes of Antiretroviral Treatment Services for People Living with HIV/AIDS in VietnamPopulation health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluationDeterminants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, ChinaSevere morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine CohortUse of surveillance data on HIV diagnoses with HIV-related symptoms to estimate the number of people living with undiagnosed HIV in need of antiretroviral therapyHow many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance dataPlasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.When to start antiretroviral therapy in resource-limited settings: a human rights analysis.Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals.Effect of early versus deferred antiretroviral therapy for HIV on survival.High acceptability of rapid HIV self-testing among a diverse sample of MSM from Buenos Aires, ArgentinaActivation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients.Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania.Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in IndiaInfrequent HIV testing and late HIV diagnosis are common among a cohort of black men who have sex with men in 6 US cities.The economic burden of late entry into medical care for patients with HIV infection.Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational studyPhenotypic alteration of neutrophils in the blood of HIV seropositive patients.CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeImmune status at presentation for HIV clinical care in Rio de Janeiro and BaltimoreMorbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project PhidisaEvaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis.The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with menPrevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South AfricaAIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'IvoirePredictors of disease progression in HIV infection: a review.CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHEREIncreased level of arginase activity correlates with disease severity in HIV-seropositive patients.Patients Presenting with Advanced Human Immunodeficiency Virus Disease: Epidemiological Features by Age Group.When should antiretroviral therapy for HIV be started?Impact of age on markers of HIV-1 diseaseEpidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease.Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.
P2860
Q27690715-AEB1338B-BBF2-4429-9D69-3EC6175C2601Q28354164-5A239351-1BFE-4353-BC09-0398EC0054DEQ28485280-7CF25EC2-4BE0-4304-B697-E8230099F17DQ28537961-1F12B78A-1ED6-428C-8928-D6878A2CAA2EQ28541356-2540428D-A545-4D7A-ACD9-838DD0A0E2ADQ30000634-B8AB4E57-4828-46D1-8C8E-9C9CFDB3EC17Q31039707-A0D9368A-B5A3-4BE1-9A94-66B739F7D031Q33284948-3E39CBFA-8BB6-46A3-BDC2-15F3FDF46B68Q33534635-ECDBB41B-AC9D-44C8-9AEC-1E84812631A2Q33548096-A66D9CE5-B77F-4CDD-890D-5920DA928BBBQ33654674-2B7FF3F4-2F64-48DE-98B1-575554AACE2CQ33789114-80CE6579-8234-4C32-BD60-8DBDB18B733FQ33865910-F2F92BF4-BD22-4995-B1F5-BC074159E1E2Q33943429-FC7A8EF9-6FA6-405C-9ED2-E155F57682A9Q34011661-1846CCB1-F480-4B8D-9F0F-DE250A210D73Q34049044-8C4FD9CC-B66D-4BE3-A083-DD5929133DBFQ34216522-9FA03A38-FD65-427E-90D1-AD8BBD5C5FBCQ34275769-91806359-5FB1-445D-82E5-18408DF522A3Q34422229-87C01F14-4980-4D5F-938A-0A8283E18DAFQ34497355-719CD3F8-6363-45BD-BB39-B75DA0AEC93BQ34663606-16E6232C-A75C-409A-97C3-0EEF9D50A3EFQ34903835-39904F1C-9EFF-49F3-9A69-43AA612F592AQ34988287-23E06E3E-72B7-49D9-A43A-ED609036818EQ35111365-E11D3C1F-9592-4AFB-B812-2B2BB99BBC43Q35124959-67A226D3-2B79-41C6-87D5-0147DBC54A65Q35205910-4AA59DE3-D1B2-49CD-B568-9D817034D7C7Q35345807-8E398E16-32E3-4DDA-9FB6-81023F15BC74Q35584415-FC3CD7B2-6F9A-4344-B1A6-0B7EE60C3654Q35624701-CF68FB17-BE9A-44F7-AD65-F8A8B04426FBQ35632074-C0240A80-65D9-4836-B148-C7EE8C513A2EQ35745688-63013CCF-9A6E-4594-A3AE-6957E6EEE9AFQ35834337-A57F2E19-56D1-4147-9575-F1D1A8F8A949Q35842386-2301918F-6D94-4174-99CB-5AAE3F157144Q36330142-BDAD96AD-ABBF-4713-B360-7AF4C94F88FEQ36509903-7611211D-9A85-4A03-ACF1-5F33549C5CC7Q36705908-9BBFE199-CB77-4BFC-A697-6AB6145C37C5Q36763762-FECB54DF-2E4D-4ED6-BA3A-CF6178C0C698Q36809170-2B91830C-8AE3-428B-B7DA-987DA4DDD933Q36914893-47EF5FB8-01C0-4160-BFEF-F32A76405346Q37028220-4315BD88-22B5-49A6-BCC3-E9D5B079B6D4
P2860
Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@en
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@nl
type
label
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@en
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@nl
prefLabel
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@en
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@nl
P2093
P921
P1433
P1476
Short-term risk of AIDS accord ...... reated in the monotherapy era.
@en
P2093
A Phillips
CASCADE Collaboration
Patrizio Pezzotti
P356
10.1097/00002030-200401020-00006
P407
P577
2004-01-01T00:00:00Z